Theravance Biopharma R&d Ip, LLC

Steven D E Sullivan

Paul Ross Fatheree

Cameron Smith

Lori Jean Van Orden

Gary E L Brandt

Glenn D Crater

Melanie A Kleinschek

Melissa Fleury

Lan Jiang

John R Jacobsen

Anne-Marie Beausoleil

Adam D Hughes

Jennifer Kozak

Svitlana Kulyk

Christina Owens

Miroslav Rapta

Venkat R Thalladi

Pierre-Jean Colson

Erik Fenster

Paul Allegretti

Marta Dabros

Mandy Loo

Gene Timothy Fass

Gary Brandt

Noah M Benjamin

The invention provides compounds of formula (I): which contain a 4-membered heterocyclic amide, where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.

JAK inhibitors containing a 4-membered heterocyclic amide

The present disclosure provides inhibitors of activin receptor-like kinase 5 (ALK5). Also disclosed are methods to modulate the activity of ALK5 and methods of treatment of disorders mediated by ALK5.

ALK5 inhibitors

The invention provides compounds of formula (I): wherein X is and the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.

JAK kinase inhibitor compounds for treatment of respiratory disease

The invention provides compounds of formula (I): where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.

Fused imidazo-piperidine JAK inhibitors

Substituted pyridines and methods of use

The invention provides compounds of formula (I):  which contain a 4-membered heterocyclic amide, where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.

Growing community of inventors

San Francisco, CA, United States of America

Steven D E Sullivan